[1]Iovance Biotherapeutics completes biologics license application (BLA) submission for lifileucel in advanced melanoma. News release. Iovance Biotherapeutics. March 24, 2023. Accessed March 27, 2023. https://ir.iovance.com/news-releases/3/2023
[2]Iovance Biotherapeutics announces updated clinical data for lifileucel in advanced melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting. News release. Iovance Biotherapeutics. November 10, 2022. Accessed March 27, 2023. https://ir.iovance.com/news-releases/11/2022